Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
about
Cross-regulation of TNF and IFN-alpha in autoimmune diseasesAnti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyFunctional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organizationMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesA registry of ankylosing spondylitis registries and prospects for global interfacingCreation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonistWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?The Role of Laboratory Tests in Crohn's DiseaseAttitudes about tuberculosis prevention in the elimination phase: a survey among physicians in GermanyOne-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort StudyPotential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracingRisk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.CD4-CD8-αβ and γδ T cells display inflammatory and regulatory potentials during human tuberculosis.Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisClinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland.Genetic polymorphisms in TNF genes and tuberculosis in North Indians."It's so hard taking pills when you don't know what they're for": a qualitative study of patients' medicine taking behaviours and conceptualisation of medicines in the context of rheumatoid arthritisRisk of tuberculosis reactivation with rituximab therapy.Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaAssociation of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Management of ANCA-associated vasculitis: Current trends and future prospectsPreventing infective complications in inflammatory bowel disease.Initiation of rheumatoid arthritis treatments and the risk of serious infections.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.TNFα-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesClinical implications of shared genetics and pathogenesis in autoimmune diseases.Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis.Small-molecule inhibitors of the interaction between TNF and TNFR.Anti-TNFα antibody infliximab treatment for an infant with fistulising Crohn's disease.
P2860
Q24556513-758C20F4-EE7C-4527-8749-CF5AF9561069Q24673716-495B0188-DD65-4166-8311-68831E15A2C1Q24805033-DD018470-2869-46F0-A835-D6CD531FE70BQ26824970-33C1F614-9119-43CA-8FA4-6906C7B0C10BQ26852081-68032864-195D-412B-862A-8B4140B3C311Q26991673-0629DE13-4EAA-4918-95C5-5BB3E7C74F32Q27026669-463E6D42-63C2-45BB-968A-E13556F26D6EQ27649040-38FA8298-B106-4824-A950-59559EC619ADQ27687191-9956B39C-F6E6-4E35-85AA-ECCB7C4F036CQ28074148-94FB6EDF-31C3-4B3E-AB36-8B52FBF2EC06Q28075045-C6512CCA-FE8C-4EEE-9ABC-5294F0439952Q28397652-6C084D92-E11C-4A5F-9944-8A265F72F571Q28553438-04DF1B39-DA0F-4B49-9A9B-5E2B74F42FC4Q28750276-046ACC47-E08B-4AD3-B174-4F08A054D69BQ30240183-BBC050B4-59CA-41BA-B2FA-D28DE1EA3673Q30397234-79093C3C-4A10-423A-908F-878F33F9D157Q30412650-58E85A52-09CA-4754-8420-34CA7313714EQ30891297-8EB0537B-BA5B-4DF2-BDD4-F0062B66D2B1Q31036925-DE7866CF-D233-4BC7-932C-5362B68E18DBQ31109167-EA2C2228-8A42-4114-A5A5-5CCD33EC14A1Q33222422-E0E7E80F-4C55-43B3-BDCE-CA6732CCD1F8Q33521526-2DBC3CFF-9DFC-4CBA-BF54-B1B8C9427EE7Q33600361-45E3567E-EEE1-418E-816E-43987D2A169AQ33604554-A11A0FD2-9B93-4A1E-9F3E-93FAF05B2F52Q33662445-997B1C27-754A-434E-B03E-63D827023690Q33667789-C8ED41D4-5B5E-4A4E-8B56-85F26139CFA4Q33819684-B19E5204-2BE7-44C5-9797-84D96CE67719Q33939033-F26C361B-195B-402F-87A0-52CA24A349C4Q33947599-146A26DE-FA8F-4360-BDDE-FF0DB96D4BC8Q34008766-8BF63CA7-1174-4D4D-B944-ECCBE7A8689EQ34019267-1897978F-7E01-4440-9886-FC860D7213F1Q34027648-175316F1-4D23-43A8-93C5-B81A669EF4A3Q34065405-00085287-1F4A-404F-8EA7-6D78F51FE39DQ34152994-8D7E22C1-FA7E-4D84-B6EC-6535A989EBC8Q34170764-9DC1CB4A-CBE8-4713-B005-244DD77D3A0AQ34216770-2D9B327B-D302-4EBC-B587-C66EABC7F74CQ34365119-3C5E147C-6E15-4057-8FE4-0A18FDBC54C7Q34378280-CFECCD52-7235-4C63-8717-7FFBB5144351Q34519187-76828747-EFEA-438B-BF26-61CF6C003BECQ34525280-667B0649-A115-40CC-B524-814E1639DE8C
P2860
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment of rheumatoid arthri ...... er active-surveillance report.
@en
Treatment of rheumatoid arthri ...... er active-surveillance report.
@nl
type
label
Treatment of rheumatoid arthri ...... er active-surveillance report.
@en
Treatment of rheumatoid arthri ...... er active-surveillance report.
@nl
prefLabel
Treatment of rheumatoid arthri ...... er active-surveillance report.
@en
Treatment of rheumatoid arthri ...... er active-surveillance report.
@nl
P2093
P2860
P356
P1476
Treatment of rheumatoid arthri ...... er active-surveillance report.
@en
P2093
BIOBADASER Group
Emilio Martín Mola
Juan J Gómez-Reino
Maria Dolores Montero
Vicente Rodríguez Valverde
P2860
P304
P356
10.1002/ART.11137
P577
2003-08-01T00:00:00Z